Abstract
Activating Ras mutations are associated with ~30% of all human cancers, which often respond poorly to standard therapies. The four Ras isoforms are therefore highly attractive targets for anticancer drug discovery. However, Ras proteins function through protein-protein interactions and their surfaces lack any major pockets for small molecules to bind; as a result they have been declared “undruggable” for the past 30 years. Several breakthroughs during the past few years may finally remove Ras from the list of undruggable proteins. This mini-review discusses the current approaches to developing inhibitors especially cyclic peptides that physically block the interaction between Ras and its downstream effector proteins, which is potentially the most effective approach for treating Ras mutant cancers.
Keywords: Cancer, Cell signaling, Inhibition, Macrocycles, Protein-protein interaction, Ras.
Mini-Reviews in Medicinal Chemistry
Title:Direct Inhibitors of Ras-Effector Protein Interactions
Volume: 16 Issue: 5
Author(s): Punit Upadhyaya, Walaa Bedewy and Dehua Pei
Affiliation:
Keywords: Cancer, Cell signaling, Inhibition, Macrocycles, Protein-protein interaction, Ras.
Abstract: Activating Ras mutations are associated with ~30% of all human cancers, which often respond poorly to standard therapies. The four Ras isoforms are therefore highly attractive targets for anticancer drug discovery. However, Ras proteins function through protein-protein interactions and their surfaces lack any major pockets for small molecules to bind; as a result they have been declared “undruggable” for the past 30 years. Several breakthroughs during the past few years may finally remove Ras from the list of undruggable proteins. This mini-review discusses the current approaches to developing inhibitors especially cyclic peptides that physically block the interaction between Ras and its downstream effector proteins, which is potentially the most effective approach for treating Ras mutant cancers.
Export Options
About this article
Cite this article as:
Upadhyaya Punit, Bedewy Walaa and Pei Dehua, Direct Inhibitors of Ras-Effector Protein Interactions, Mini-Reviews in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1389557515666151001141713
DOI https://dx.doi.org/10.2174/1389557515666151001141713 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Trends in Biotechnological Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry FDG-PET/CT Imaging of Infected Bones and Prosthetic Joints
Current Molecular Imaging (Discontinued) Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Current Medicinal Chemistry Beyond Cox-Inhibition: ‘Side-Effects’ of Ibuprofen on Neoplastic Development and Progression
Current Pharmaceutical Design Stereoselective Metabolic and Pharmacokinetic Analysis of the Chiral Active Components from Herbal Medicines
Current Pharmaceutical Analysis Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Development of Specific New ELISA for Bioanalysis of Cetuximab: A Monoclonal Antibody Used for Cancer Immunotherapy
Current Pharmaceutical Analysis Application of Carbon Nanomaterials in Gene Delivery for Endogenous RNA Interference <i>In Vitro</i> and <i>In Vivo</i>
Current Pharmaceutical Design Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-Small Cell Lung and Colorectal Cancers: Design, Synthesis, <i>In silico</i> and <i>In vitro</i> Studies Providing Mechanistic Insight into Their Anticancer Potencies
Medicinal Chemistry 3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Medicinal Chemistry Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics